275 related articles for article (PubMed ID: 32747522)
1. Effect of fremanezumab on quality of life and productivity in patients with chronic migraine.
Lipton RB; Cohen JM; Gandhi SK; Yang R; Yeung PP; Buse DC
Neurology; 2020 Aug; 95(7):e878-e888. PubMed ID: 32747522
[TBL] [Abstract][Full Text] [Related]
2. Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study.
Spierings ELH; Ning X; Ramirez Campos V; Cohen JM; Barash S; Buse DC
Headache; 2021 Oct; 61(9):1376-1386. PubMed ID: 34374086
[TBL] [Abstract][Full Text] [Related]
3. Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine.
Ashina M; Cohen JM; Gandhi SK; Du E
Headache; 2021 Jun; 61(6):916-926. PubMed ID: 34115380
[TBL] [Abstract][Full Text] [Related]
4. Improved quality of life with fremanezumab in Japanese and Korean patients with episodic and chronic migraine: Results of two multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trials.
Matsumori Y; Ishida M; Iba K; Kim BK; Ning X; Nakai M; Koga N
Headache; 2023 Oct; 63(9):1304-1313. PubMed ID: 37602905
[TBL] [Abstract][Full Text] [Related]
5. The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study.
Silberstein SD; Cohen JM; Seminerio MJ; Yang R; Ashina S; Katsarava Z
J Headache Pain; 2020 Sep; 21(1):114. PubMed ID: 32958075
[TBL] [Abstract][Full Text] [Related]
6. Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials.
Silberstein SD; Cohen JM; Yang R; Gandhi SK; Du E; Jann AE; Marmura MJ
J Headache Pain; 2021 Jan; 22(1):2. PubMed ID: 33413075
[TBL] [Abstract][Full Text] [Related]
7. Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study.
Lipton RB; Cohen JM; Galic M; Seminerio MJ; Yeung PP; Aycardi E; Bigal ME; Bibeau K; Buse DC
Headache; 2021 Apr; 61(4):662-672. PubMed ID: 33891348
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study.
Goadsby PJ; Silberstein SD; Yeung PP; Cohen JM; Ning X; Yang R; Dodick DW
Neurology; 2020 Nov; 95(18):e2487-e2499. PubMed ID: 32913018
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies.
Nahas SJ; Naegel S; Cohen JM; Ning X; Janka L; Campos VR; Krasenbaum LJ; Holle-Lee D; Kudrow D; Lampl C
J Headache Pain; 2021 Nov; 22(1):141. PubMed ID: 34819017
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.
Sakai F; Suzuki N; Kim BK; Igarashi H; Hirata K; Takeshima T; Ning X; Shima T; Ishida M; Iba K; Kondo H; Koga N
Headache; 2021 Jul; 61(7):1092-1101. PubMed ID: 34324700
[TBL] [Abstract][Full Text] [Related]
11. Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.
McAllister P; Cohen JM; Campos VR; Ning X; Janka L; Barash S
J Headache Pain; 2022 Aug; 23(1):112. PubMed ID: 36038833
[TBL] [Abstract][Full Text] [Related]
12. Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine.
Brandes JL; Kudrow D; Yeung PP; Sakai F; Aycardi E; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y
Cephalalgia; 2020 Apr; 40(5):470-477. PubMed ID: 31752521
[TBL] [Abstract][Full Text] [Related]
13. No "Wearing-Off Effect" Seen in Quarterly or Monthly Dosing of Fremanezumab: Subanalysis of a Randomized Long-Term Study.
Blumenfeld AM; Stevanovic DM; Ortega M; Cohen JM; Seminerio MJ; Yang R; Jiang B; Tepper SJ
Headache; 2020 Nov; 60(10):2431-2443. PubMed ID: 33009665
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial.
Spierings ELH; Kärppä M; Ning X; Cohen JM; Campos VR; Yang R; Reuter U
J Headache Pain; 2021 Apr; 22(1):26. PubMed ID: 33863272
[TBL] [Abstract][Full Text] [Related]
15. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.
Dodick DW; Silberstein SD; Bigal ME; Yeung PP; Goadsby PJ; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y; Aycardi E
JAMA; 2018 May; 319(19):1999-2008. PubMed ID: 29800211
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and quality-of-life improvements with fremanezumab treatment in patients with difficult-to-treat migraine with associated neurological dysfunction.
Lampl C; Rapoport AM; Cohen JM; Barash S; Ramirez Campos V; Seminerio MJ; Ning X; Silberstein SD
Eur J Neurol; 2022 Jul; 29(7):2129-2137. PubMed ID: 35302681
[TBL] [Abstract][Full Text] [Related]
17. Fremanezumab for the Preventive Treatment of Chronic Migraine.
Silberstein SD; Dodick DW; Bigal ME; Yeung PP; Goadsby PJ; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y; Aycardi E
N Engl J Med; 2017 Nov; 377(22):2113-2122. PubMed ID: 29171818
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.
Sakai F; Suzuki N; Kim BK; Tatsuoka Y; Imai N; Ning X; Ishida M; Nagano K; Iba K; Kondo H; Koga N
Headache; 2021 Jul; 61(7):1102-1111. PubMed ID: 34323290
[TBL] [Abstract][Full Text] [Related]
19. Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study.
MaassenVanDenBrink A; Terwindt GM; Cohen JM; Barash S; Campos VR; Galic M; Ning X; Kärppä M
J Headache Pain; 2021 Dec; 22(1):152. PubMed ID: 34922436
[TBL] [Abstract][Full Text] [Related]
20. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial.
Ferrari MD; Diener HC; Ning X; Galic M; Cohen JM; Yang R; Mueller M; Ahn AH; Schwartz YC; Grozinski-Wolff M; Janka L; Ashina M
Lancet; 2019 Sep; 394(10203):1030-1040. PubMed ID: 31427046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
